<DOC>
	<DOC>NCT00277914</DOC>
	<brief_summary>To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.</brief_summary>
	<brief_title>Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
	<criteria>1. Women over 18 and premenopausal 2. FSDSR above 14 3. Willingness to try to have sexual activity at least monthly 4. Willingness to use an electronic diary daily 5. Stable, monogamous, heterosexual relationship for at least one year 6. Medically acceptable method of contraception 1. Clinically relevant conditions which might interfere with the patient's abil ity to participate in the trial 2. Specified medications 3. Sexual function affected by medication 4. Drug dependence or abuse 5. Sexual partner needing treatment 6. PeriMenopause or Menopause (surgical or otherwise) 7. Pregnancy 8. Pelvic Inflammatory Disease 9. Major depressive Episode 10. Significant ECG abnormalities 11. Significant Neurologic findings 12. Significant GI, Hepatic, Cardiovascular, Renal, Hematologic, Immunologic or Respiratory findings 13. Uncorrected thyroid or endocrine disease 14. Uncontrolled Glaucoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>